10-Q: Cencora Q1 2026: Revenue Up 5.5%, Strategic Acquisitions Drive Growth

Cencora reports a 5.5% revenue increase in Q1 fiscal 2026, driven by U.S. Healthcare Solutions and strategic acquisitions, despite an asset impairment.

Summary

• Revenue increased by $4.4 billion, or 5.5%, to $85.93 billion for the three months ended December 31, 2025, compared to $81.49 billion in the prior year quarter.
• U.S. Healthcare Solutions revenue grew by $3.7 billion, or 5.0%, primarily due to overall market growth, including a $1.0 billion (10.9%) increase in GLP-1 class products.
• International Healthcare Solutions revenue rose by $0.7 billion, or 9.6%, mainly from increased sales in the European distribution business.
• Gross profit increased by $514.0 million, or 20.1%, to $3.07 billion, driven by both segments and a $70.2 million increase in LIFO credit.
• Net income attributable to Cencora, Inc. was $559.6 million ($2.87 diluted EPS) for the three months ended December 31, 2025, up from $488.6 million ($2.50 diluted EPS) in the prior year.
• Operating income increased by 7.7% to $760.4 million.
• The company completed the acquisition of an 85% interest in Retina Consultants of America (RCA) on January 2, 2025, for $4.04 billion in cash and contingent consideration.
• Subsequent to the quarter, on February 2, 2026, Cencora acquired the majority of outstanding equity interests in OneOncology for approximately $4.6 billion in cash.
• A goodwill impairment of $165.7 million was recorded related to the U.S. Consulting Services business, which is classified as held for sale.
• The company's Board increased the quarterly dividend by 9% from $0.55 to $0.60 per share in November 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong quarter with robust revenue and profit growth, driven by strategic acquisitions and favorable market trends in specialty pharmaceuticals, despite increased debt and an asset impairment.

Positives

• Revenue increased by 5.5% to $85.93 billion.
• Gross profit increased by 20.1% to $3.07 billion.
• Net income attributable to Cencora, Inc. increased to $559.6 million from $488.6 million.
• Diluted EPS increased to $2.87 from $2.50.
• U.S. Healthcare Solutions revenue grew 5.0%, with GLP-1 products contributing $1.0 billion (10.9%) in increased sales.
• International Healthcare Solutions revenue grew 9.6%.
• Successful acquisition of Retina Consultants of America (RCA) and subsequent acquisition of OneOncology, expanding specialty healthcare solutions.
• Increased quarterly dividend by 9% to $0.60 per share.
• Received an $86.8 million credit from a derivative lawsuit settlement.
• LIFO credit increased by $70.2 million, primarily due to a decline in manufacturer prices for certain brand pharmaceutical products.
• Effective tax rate slightly decreased to 20.1% from 20.4%.

Negatives

• Cash and cash equivalents decreased significantly from $4.36 billion to $1.75 billion.
• Operating expenses increased by $459.8 million, or 24.8%, primarily due to the RCA acquisition and asset impairment.
• International Healthcare Solutions operating income decreased by $23.0 million, or 13.9%.
• Operating income in "Other" segment decreased by $5.9 million, or 6.1%.
• Interest expense, net, increased by $44.5 million, or 159.2%, due to new debt issuances.
• Recorded a goodwill impairment of $165.7 million related to the U.S. Consulting Services business.
• Losses of a grocery customer and an oncology customer impacted U.S. Healthcare Solutions revenue.
• Cash used in operating activities was $2.3 billion, primarily due to increases in inventories ($3.5 billion) and accounts receivable ($0.8 billion).
• Foreign currency translation adjustments resulted in a loss of $6.8 million.

Risks

• Ability to respond to general macroeconomic conditions and geopolitical uncertainties, including changes or uncertainties in U.S. policies, financial market volatility and disruption, inflationary concerns, interest and currency exchange rates, and uncertain economic conditions in the United States and abroad.
• Ability to respond to changes or uncertainty in the policies of countries and regions in which the company does business, including with respect to trade policies, tariffs, or other protective measures, which can disrupt global operations, as well as the operations of customers and suppliers.
• Ability to respond to changes to customer or supplier mix and payment terms, or to changes to manufacturer pricing.
• The retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers.
• Competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for products and services.
• Risks associated with strategic, long-term relationships with Walgreens and Boots UK Ltd., including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement.
• Risks that acquisitions of or investments in businesses, including the acquisitions of Retina Consultants of America (RCA) and OneOncology, LLC (OneOncology) fail to achieve expected or targeted future financial and operating performance and results.
• Ability to manage and complete divestitures.
• Ability to effectively manage growth.
• Ability to maintain the strength and security of information technology systems.
• Any inability or failure by the company, its service providers, or third-party business partners to anticipate or detect data or information security breaches or other cyberattacks, including due to the evolution of artificial intelligence (AI) or otherwise.
• Ability to manage foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations.
• Risks associated with international operations, including changes to laws and regulations in countries where the company does business, financial and other impacts of macroeconomic and geopolitical trends and events, including rising nationalism, the conflict in Ukraine, evolving conditions in the Middle East, and related regional and global ramifications.
• Unfavorable trends in brand and generic pharmaceutical pricing, including the rate or frequency of price inflation or deflation.
• Changes in the U.S. healthcare and regulatory environment, including changes that could impact vaccine and prescription drug coverage, reimbursement, pricing, distribution, and contracting, as well as other regulatory changes from the Executive Branch, including executive orders, and resulting from the One Big Beautiful Bill Act (OBBBA).
• The bankruptcy, insolvency, or other credit failure of a significant supplier or customer.
• Ability to comply with increasing governmental regulations regarding the pharmaceutical supply chain.
• Continued federal and state government enforcement initiatives to detect and prevent suspicious orders of opioid medications, controlled substance medications, or other medications, and the diversion of such medications.
• Uncertainties associated with litigation, including the outcome of any legal or governmental proceedings that may be instituted against the company, continued investigation, prosecution or suit by federal and state governmental entities and other parties of alleged violations of laws and regulations regarding opioid medications, controlled substance medications, or other medications, and any related disputes.
• The outcome of any legal or governmental proceedings that may be instituted against the company, including material adverse resolution of pending legal proceedings.
• Risks generally associated with data privacy regulation and the protection and international transfer of proprietary business information or personal data.
• Ability to protect reputation.
• Ability to address events outside of control, such as widespread public health issues, natural disasters, government policy changes, and political events.
• The impairment of goodwill or other intangible assets resulting in a charge to earnings.
• Inflation in the global and U.S. economies has impacted certain operating expenses, and if it persists or increases, operations and financial results could be adversely affected, particularly in certain global markets.

Future Outlook

The company expects future revenue growth to be influenced by industry trends like drug utilization (e.g., GLP-1 products), new brand therapies and vaccines, increased generic/biosimilar availability, pricing dynamics, economic conditions, currency exchange rates, competition, customer consolidation, and regulatory changes. It anticipates investing approximately $900 million in capital expenditures during fiscal 2026, focusing on expanding and enhancing its distribution network and technology initiatives. The company expects future cash flows from operations and borrowings to be sufficient to fund ongoing cash requirements, including opioid litigation payments over the next 13 years.

Management Comments

• "Revenue increased by $4.4 billion, or 5.5%, from the prior year quarter primarily due to growth in both reportable segments."
• "U.S. Healthcare Solutions revenue increased by $3.7 billion, or 5.0%, from the prior year quarter primarily due to overall market growth largely driven by unit volume growth, including increased sales of specialty products to health systems and physician practices and products labeled for diabetes and/or weight loss in the GLP-1 class of $1.0 billion, or 10.9%, offset in part by a decrease in sales due to losses of a grocery customer and an oncology customer."
• "Gross profit increased by $514.0 million, or 20.1%, from the prior year quarter primarily due to the increase in gross profit in both reportable segments and a $70.2 million increase in the LIFO credit."
• "Our operating results have generated cash flows, which, together with availability under our debt agreements and credit terms from suppliers, have provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and purchases of shares of our common stock."
• "Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements, including the opioid litigation payments that will be made over the next 13 years."

Industry Context

StockSavvy.ai notes that Cencora's strong performance in U.S. Healthcare Solutions, particularly the $1.0 billion increase in GLP-1 class products, reflects a significant industry trend towards diabetes and weight loss medications. The strategic acquisitions of Retina Consultants of America and OneOncology position Cencora to further capitalize on the growing specialty pharmaceutical and oncology markets, aligning with broader healthcare industry consolidation and focus on high-growth therapeutic areas. The increase in LIFO credit due to declining manufacturer prices for certain brand pharmaceuticals suggests a dynamic pricing environment that benefits distributors.

Comparison to Industry Standards

• The company's 5.5% revenue growth is solid for a large pharmaceutical distributor, especially with significant contributions from specialty products and GLP-1s, which are high-growth areas in the pharmaceutical market.
• The 20.1% gross profit increase, significantly outpacing revenue growth, suggests effective cost management and favorable product mix, potentially outperforming peers heavily reliant on lower-margin traditional distribution.
• The acquisition of OneOncology for $4.6 billion, following RCA, indicates an aggressive strategy to expand into high-value, physician-led specialty platforms, a trend seen across the healthcare services sector as companies seek to integrate and control more of the patient care continuum.
• The increase in interest expense by 159.2% highlights the impact of rising interest rates and increased debt financing for acquisitions, which could be a concern if not managed effectively compared to industry peers with lower debt burdens.

Corporate Governance

Legal Proceedings

• Opioid Lawsuits and Investigations: Multidistrict Litigation (MDL) proceedings are ongoing. The Fourth Circuit vacated a West Virginia District Court judgment and remanded the case, with a hearing scheduled for March 24, 2026. The Distributor Settlement Agreement, effective April 2, 2022, has resolved a substantial majority of opioid lawsuits from state and local governmental entities. In the Baltimore opioid case, a jury found ABDC liable for public nuisance, initially assessing $74 million in compensatory damages, which was later reduced to $14.4 million by the Baltimore Circuit Court, with an additional $28 million assessed for abatement measures. Appeals are ongoing. The accrued litigation liability related to opioid settlements is $4.3 billion as of December 31, 2025, with $426.2 million estimated to be paid prior to December 31, 2026. The Department of Justice filed a civil complaint on December 29, 2022, alleging Controlled Substances Act violations, with fact discovery due August 12, 2026, and expert discovery due March 15, 2027.
• Shareholder Securities Litigation: A derivative action alleging breach of fiduciary duty was settled, with the Delaware Court of Chancery approving the settlement on November 13, 2025. The company received an $86.8 million credit from insurance carriers on December 30, 2025, related to this settlement.
• Subpoenas, Ongoing Investigations, and Other Contingencies: A qui tam complaint against U.S. Bioservices Corporation related to billing and overpayments was dismissed, but the relator has appealed to the Second Circuit. A criminal investigation into MWI Veterinary Supply Co. (MWI) regarding compliance with animal health product shipments resulted in an agreement in principle in October 2024, leading to a $49.1 million litigation expense accrual in fiscal 2024.

Stakeholder Impact

• Shareholders: Positive impact from increased revenue, gross profit, net income, and dividend increase. Potential positive impact from strategic acquisitions. Potential negative impact from increased debt and goodwill impairment. Resolution of shareholder litigation is positive.
• Customers: Continued growth in specialty products and GLP-1s indicates strong customer demand. Loss of a grocery and oncology customer is a negative.
• Employees: Workforce reductions mentioned under restructuring costs.
• Creditors: Increased debt levels due to acquisitions, but facilities are compliant with covenants.
• Suppliers: Impacted by changes in manufacturer pricing (LIFO credit).

Next Steps

• Continue to litigate and prepare for trial in opioid lawsuits and vigorously defend against threatened lawsuits.
• Submit additional briefing and attend a hearing on March 24, 2026, for the remanded West Virginia opioid case.
• File appellee brief to the Second Circuit by February 17, 2026, in the U.S. Bioservices Corporation qui tam complaint appeal.
• Fact discovery deadline for the Department of Justice civil complaint is August 12, 2026.
• Expert discovery deadline for the Department of Justice civil complaint is March 15, 2027.
• Invest approximately $900 million in capital expenditures during fiscal 2026, focusing on distribution network expansion and technology initiatives.
• Continue to pay quarterly cash dividends.
• Robert P. Mauch's Rule 10b5-1 trading arrangement allows sales prior to the earlier of October 30, 2026, or completion of all sales under the plan.
• Elizabeth S. Campbell's Rule 10b5-1 trading arrangement allows sales prior to the earlier of December 18, 2026, or completion of all sales under the plan.
• James F. Cleary's Rule 10b5-1 trading arrangement allows sales prior to the earlier of December 31, 2026, or completion of all sales under the plan.

Key Dates

Recommendation

Cencora demonstrates strong operational performance with significant revenue and gross profit growth, driven by strategic acquisitions in high-growth healthcare segments like specialty pharmaceuticals and oncology. The dividend increase signals confidence. However, the substantial increase in debt to finance these acquisitions, coupled with a significant decrease in cash and cash equivalents, introduces financial leverage risk. The ongoing opioid litigation, despite a partial settlement credit, remains a material long-term liability. While the strategic direction is positive, the increased debt burden and existing legal uncertainties warrant a "hold" recommendation, advising investors to monitor debt reduction strategies and the ultimate resolution of legal matters before considering further investment.

Keywords

Healthcare distribution, pharmaceutical, specialty pharmaceuticals, Cencora, 10-Q, financial report, Q1 2026, revenue growth, gross profit, operating income, net income, GLP-1, Retina Consultants of America, OneOncology, acquisitions, debt financing, opioid litigation, share repurchase, dividends, U.S. Healthcare Solutions, International Healthcare Solutions, animal health, LIFO credit